Teva Under Federal Scrutiny Over Potential FCA Breaches

Law360, Los Angeles (February 10, 2014, 4:01 PM EST) -- Teva Pharmaceuticals Industries Ltd. told investors it is under a federal investigation for potential violations of the False Claims Act, according to an annual report filed with the U.S. Securities and Exchange Commission on Monday.

The Israeli drugmaker said the U.S. attorney in New York demanded on Jan. 8 to see documents related to sales, marketing and promotion of two of its drugs, the top-selling Copaxone and Azilect. Teva said it is complying with the subpoenas.

Representatives for Teva did not immediately respond to requests for...
To view the full article, register now.